Clinical and Laboratory Outcomes during the Treatment of Rheumatoid Arthritis with Methotrexate

G. W. Cannaon Division of Rheumatology, Department of Internal Medicine, and the Department of Family and Community Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA; Medical Service, VA Medical Center, Salt Lake City, Utah, USA

J. C. Reading Division of Rheumatology, Department of Internal Medicine, and the Department of Family and Community Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA; Medical Service, VA Medical Center, Salt Lake City, Utah, USA

J. R. Ward Division of Rheumatology, Department of Internal Medicine, and the Department of Family and Community Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA; Medical Service, VA Medical Center, Salt Lake City, Utah, USA

L. J. Blonquist Division of Rheumatology, Department of Internal Medicine, and the Department of Family and Community Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA; Medical Service, VA Medical Center, Salt Lake City, Utah, USA

L. B. Collette Division of Rheumatology, Department of Internal Medicine, and the Department of Family and Community Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA; Medical Service, VA Medical Center, Salt Lake City, Utah, USA

Abstract

Ten clinical and three laboratory outcomes were evaluated in 86 patients completing a double-blind placebo-controlled trial of methotrexate in rheumatoid arthritis. The improvement in all measured outcomes was statistically significantly better in patients receiving methotrexate than in patients receiving placebo. The correlations of the changes in outcome measures were calculated to determine if improvement in one parameter was associated with improvement in other clinical parameters. Associations between different clinical outcomes were often statistically significant. Associations between laboratory outcomes were also often statistically significant. However, the association between clinical outcomes and laboratory outcomes was generally poor.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Clinical and Laboratory Outcomes during the Treatment of Rheumatoid Arthritis with Methotrexate

Related Research Data

Information for

Open access

Opportunities

Help and information

Clinical and Laboratory Outcomes during the Treatment of Rheumatoid Arthritis with Methotrexate

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related Research Data

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature